Knowledge of the Serological Response to the Third BNT162b2 Vaccination May Influence Compliance of Healthcare Workers to Booster Dose.

SARS-CoV-2 booster compliance healthcare workers vaccination

Journal

Antibodies (Basel, Switzerland)
ISSN: 2073-4468
Titre abrégé: Antibodies (Basel)
Pays: Switzerland
ID NLM: 101587489

Informations de publication

Date de publication:
01 Aug 2024
Historique:
received: 01 04 2024
revised: 02 07 2024
accepted: 23 07 2024
medline: 27 8 2024
pubmed: 27 8 2024
entrez: 27 8 2024
Statut: epublish

Résumé

Previous studies showed that the fourth SARS-CoV-2 vaccine dose has a protective effect against infection, as well as against severe disease and death. This study aimed to examine whether knowledge of a high-level antibody after the third dose may reduce compliance to the fourth booster dose among healthcare workers (HCWs). We conducted a prospective cohort study among HCWs vaccinated with the first three doses at Rambam Healthcare Campus, a tertiary hospital in northern Israel. Participants underwent a serological test before the fourth booster vaccine was offered to all of them, with results provided to participants. The population was divided into two groups, namely those with antibodies below 955 AU/mL and those with 955 AU/mL and higher, a cutoff found protective in a previous study. Multiple logistic regression was carried out to compare the compliance to the fourth booster between the two groups, adjusted for demographic and clinical variables. After adjusting for the confounding variables, the compliance was higher in those with antibody levels below 955 AU/mL (OR = 1.41, Knowledge of the antibody status may affect compliance with the booster dose. Considering waning immunity over time, reduced compliance may affect the protection of HCWs who declined the fourth dose.

Sections du résumé

BACKGROUND BACKGROUND
Previous studies showed that the fourth SARS-CoV-2 vaccine dose has a protective effect against infection, as well as against severe disease and death. This study aimed to examine whether knowledge of a high-level antibody after the third dose may reduce compliance to the fourth booster dose among healthcare workers (HCWs).
METHODS METHODS
We conducted a prospective cohort study among HCWs vaccinated with the first three doses at Rambam Healthcare Campus, a tertiary hospital in northern Israel. Participants underwent a serological test before the fourth booster vaccine was offered to all of them, with results provided to participants. The population was divided into two groups, namely those with antibodies below 955 AU/mL and those with 955 AU/mL and higher, a cutoff found protective in a previous study. Multiple logistic regression was carried out to compare the compliance to the fourth booster between the two groups, adjusted for demographic and clinical variables.
RESULTS RESULTS
After adjusting for the confounding variables, the compliance was higher in those with antibody levels below 955 AU/mL (OR = 1.41,
CONCLUSIONS CONCLUSIONS
Knowledge of the antibody status may affect compliance with the booster dose. Considering waning immunity over time, reduced compliance may affect the protection of HCWs who declined the fourth dose.

Identifiants

pubmed: 39189234
pii: antib13030063
doi: 10.3390/antib13030063
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Avi Magid (A)

Management, Rambam Health Care Campus, Haifa 3109601, Israel.
School of Public Health, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Khetam Hussein (K)

Management, Rambam Health Care Campus, Haifa 3109601, Israel.
The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Infection Control Unit, Rambam Health Care Campus, Haifa 3109601, Israel.

Halima Dabaja-Younis (H)

The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Pediatric Infectious Disease Unit, Rambam Health Care Campus, Haifa 3109601, Israel.

Moran Szwarcwort-Cohen (M)

Virology Laboratory, Rambam Health Care Campus, Haifa 3109601, Israel.

Ronit Almog (R)

Epidemiology Unit, Rambam Health Care Campus, Haifa 3109601, Israel.

Michal Mekel (M)

Management, Rambam Health Care Campus, Haifa 3109601, Israel.
The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.

Avi Weissman (A)

Management, Rambam Health Care Campus, Haifa 3109601, Israel.

Gila Hyams (G)

Nursing Management, Rambam Health Care Campus, Haifa 3109601, Israel.

Vardit Gepstein (V)

Management, Rambam Health Care Campus, Haifa 3109601, Israel.
The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Department of Pediatrics B, Rambam Health Care Campus, Haifa 3109601, Israel.

Netanel A Horowitz (NA)

Management, Rambam Health Care Campus, Haifa 3109601, Israel.
The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa 3109601, Israel.

Hagar Cohen Saban (H)

Nursing Management, Rambam Health Care Campus, Haifa 3109601, Israel.

Jalal Tarabeia (J)

Infection Control Unit, Rambam Health Care Campus, Haifa 3109601, Israel.
Nursing Faculty, The Max Stern Yezreel Valley College, Yezreel Valley 1930600, Israel.

Michael Halberthal (M)

Management, Rambam Health Care Campus, Haifa 3109601, Israel.
The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.

Yael Shachor-Meyouhas (Y)

Management, Rambam Health Care Campus, Haifa 3109601, Israel.
The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.

Classifications MeSH